Belantamab mafodotin, an investigational anti-B-cell maturation antigen monoclonal antibody-drug conjugate, demonstrated clinically meaningful response rates among patients with heavily pretreated multiple myeloma, according to results of the randomized phase 2 DREAMM-2 trial published in Lancet Oncology. The treatment also had a manageable safety profile.
Patients with atrial fibrillation needing stroke prevention assigned to abelacimab had very low rates of bleeding during invasive procedures, according to new data from the…
For older adults with non-STEMI, routine coronary intervention was safe but did not lower risk for death from CV causes or nonfatal MI compared with…
When presented with complex pediatric respiratory scenarios, responses from ChatGPT achieved higher performance scores than trainee doctor responses, according to a presentation at the European…
Receiving itepekimab led to a 51% lower adjusted annualized exacerbation rate in former smokers with moderate/severe COPD and exacerbation history, according to a poster presented…
A dual GLP-1/GLP-2 receptor agonist did not confer greater body weight reductions for adults with obesity and without diabetes at 12 weeks compared with placebo,…
Nearly one in 20 adults in the U.S. are estimated to have atrial fibrillation, many more than previous studies had indicated, according to new data…
BARCELONA, Spain — In this Healio Video Perspective from the European Society of Cataract and Refractive Surgeons meeting, Francesco Carones, MD, shares his clinical experience…
Use of the 2021 Chronic Kidney Disease-Epidemiology Collaboration creatinine equation led to identifying a lower rate of CKD among Korean and U.S. Asian populations, a…
Advance your clinical knowledge and earn free CME credits online at Healio.com. Choose from hundreds of activities and print your CME certificates instantly.
Advance your clinical knowledge and earn free CME credits online at Healio.com. Choose from hundreds of activities and print your CME certificates instantly.
